Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Conditions
Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma
Interventions
PHOX2B PC-CAR T Cells
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
1 Year and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma, Metastatic Retinoblastoma
Interventions
GPC2 CAR T cells
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
1 Year and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma
Interventions
Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®)
Biological · Drug
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Interventions
Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
Interventions
Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
Up to 29 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Depletion of CD3/CD19 in an autologous stem cell transplant
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
8 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Interventions
Murine CART19
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
1
States / cities
Philadelphia, Pennsylvania